Technical Analysis for KRRO - Korro Bio, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 52.32 | -3.13% | -1.69 |
KRRO closed down 3.13 percent on Wednesday, May 8, 2024, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: May 10
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New Downtrend | Bearish | -3.13% | |
| Wide Bands | Range Expansion | -3.13% | |
| Lower Bollinger Band Touch | Weakness | -3.13% |
| Alert | Time |
|---|---|
| Possible NR7 | about 19 hours ago |
| Possible Inside Day | about 19 hours ago |
| Gap Down Partially Closed | about 23 hours ago |
| Gapped Down (Partial) | about 23 hours ago |
| Down 3% | about 23 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/10/2024
Korro is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling treatment of both rare and highly prevalent diseases. Korro's lead program in AATD has demonstrated an increase of normal A1AT protein up to 85% of total A1AT protein in circulation in in vivo preclinical studies, which has the potential of disease-modifying effects and providing a differentiated therapeutic option.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Hepatology Alpha 1 Antitrypsin Alpha 1 Antitrypsin Deficiency
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Hepatology Alpha 1 Antitrypsin Alpha 1 Antitrypsin Deficiency
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 97.91 |
| 52 Week Low | 9.15 |
| Average Volume | 39,274 |
| 200-Day Moving Average | 42.59 |
| 50-Day Moving Average | 64.86 |
| 20-Day Moving Average | 64.14 |
| 10-Day Moving Average | 57.95 |
| Average True Range | 5.58 |
| RSI (14) | 34.64 |
| ADX | 26.54 |
| +DI | 12.26 |
| -DI | 26.97 |
| Chandelier Exit (Long, 3 ATRs) | 63.44 |
| Chandelier Exit (Short, 3 ATRs) | 67.74 |
| Upper Bollinger Bands | 78.75 |
| Lower Bollinger Band | 49.54 |
| Percent B (%b) | 0.1 |
| BandWidth | 45.54 |
| MACD Line | -3.89 |
| MACD Signal Line | -2.42 |
| MACD Histogram | -1.4727 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 55.22 | ||||
| Resistance 3 (R3) | 55.24 | 54.29 | 54.73 | ||
| Resistance 2 (R2) | 54.29 | 53.56 | 54.28 | 54.57 | |
| Resistance 1 (R1) | 53.31 | 53.10 | 53.80 | 53.29 | 54.41 |
| Pivot Point | 52.36 | 52.36 | 52.61 | 52.35 | 52.36 |
| Support 1 (S1) | 51.38 | 51.63 | 51.87 | 51.36 | 50.23 |
| Support 2 (S2) | 50.43 | 51.17 | 50.42 | 50.07 | |
| Support 3 (S3) | 49.45 | 50.43 | 49.91 | ||
| Support 4 (S4) | 49.43 |
